Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Haemonetics Corporation stock
Learn how to easily invest in Haemonetics Corporation stock.
Haemonetics Corporation is a medical instruments & supplies business based in the US. Haemonetics Corporation shares (HAE) are listed on the NYSE and all prices are listed in US Dollars. Haemonetics Corporation employs 2,821 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Haemonetics Corporation
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – HAE – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
Haemonetics Corporation stock price (NYSE: HAE)Use our graph to track the performance of HAE stocks over time.
Haemonetics Corporation shares at a glance
|Latest market close||$65.18|
|52-week range||$43.50 - $75.34|
|50-day moving average||$58.49|
|200-day moving average||$58.92|
|Wall St. target price||$70.17|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$0.84|
Buy Haemonetics Corporation shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Haemonetics Corporation stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Haemonetics Corporation price performance over time
|1 week (2022-06-24)||-0.12%|
|1 month (2022-06-01)||4.64%|
|3 months (2022-04-01)||2.08%|
|6 months (2021-12-31)||22.89%|
|1 year (2021-07-01)||-3.76%|
|2 years (2020-07-01)||-27.32%|
|3 years (2019-07-01)||120.19|
|5 years (2017-06-30)||65.05%|
Is Haemonetics Corporation stock undervalued or overvalued?
Valuing Haemonetics Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Haemonetics Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Haemonetics Corporation's P/E ratio
Haemonetics Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 78x. In other words, Haemonetics Corporation shares trade at around 78x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Haemonetics Corporation's PEG ratio
Haemonetics Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.1515. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Haemonetics Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Haemonetics Corporation's EBITDA
Haemonetics Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $211.2 million.
The EBITDA is a measure of a Haemonetics Corporation's overall financial performance and is widely used to measure a its profitability.
Haemonetics Corporation financials
|Revenue TTM||$993.2 million|
|Operating margin TTM||11.7%|
|Gross profit TTM||$530.8 million|
|Return on assets TTM||3.95%|
|Return on equity TTM||5.86%|
|Market capitalisation||$3.3 billion|
TTM: trailing 12 months
Haemonetics Corporation share dividends
We're not expecting Haemonetics Corporation to pay a dividend over the next 12 months.
Have Haemonetics Corporation's shares ever split?
Haemonetics Corporation's shares were split on a 2:1 basis on 2 December 2012. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Haemonetics Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Haemonetics Corporation shares which in turn could have impacted Haemonetics Corporation's share price.
Haemonetics Corporation share price volatility
Over the last 12 months, Haemonetics Corporation's shares have ranged in value from as little as $43.5 up to $75.34. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Haemonetics Corporation's is 0.4111. This would suggest that Haemonetics Corporation's shares are less volatile than average (for this exchange).
Haemonetics Corporation overview
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Haemonetics Corporation in the news
Haemonetics Completes Move to New Manufacturing Facility in Clinton, PA
Needham Sees Reasonable Forecasts For Haemonetics, With Some Tailwinds
Haemonetics (HAE) Up 28.2% Since Last Earnings Report: Can It Continue?
Frequently asked questionsWhat percentage of Haemonetics Corporation is owned by insiders or institutions?
Currently 0.671% of Haemonetics Corporation shares are held by insiders and 102.101% by institutions. How many people work for Haemonetics Corporation?
Latest data suggests 2,821 work at Haemonetics Corporation. When does the fiscal year end for Haemonetics Corporation?
Haemonetics Corporation's fiscal year ends in March. Where is Haemonetics Corporation based?
Haemonetics Corporation's address is: 125 Summer Street, Boston, MA, United States, 02110 What is Haemonetics Corporation's ISIN number?
Haemonetics Corporation's international securities identification number is: US4050241003 What is Haemonetics Corporation's CUSIP number?
Haemonetics Corporation's Committee on Uniform Securities Identification Procedures number is: 405024100
More guides on Finder
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
How to buy Warrantee (WRNT) stock when it goes public
Everything we know about the Warrantee IPO, plus information on how to buy in.
How to buy Treasure Global (TGL) stock when it goes public
Everything we know about the Treasure Global IPO, plus information on how to buy in.
How to buy BIOLIFE4D (SAVU) stock when it goes public
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
Ask an Expert